author-photo

Justin S. Waters

The Royal Marsden NHS Foundation Trust

52

Papers

3436

Citations

Citation Trend

Filter By

Papers (34) Sort By

Journal Conference Others

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (53)
Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins.

2021 Acta Oncologica
Show All
- Source
- Cite
- Save
Citations (0)
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (138)
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

2018 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (12)
Capecitabine and streptozocin +/- cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial.

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (156)
ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)